
Sangamo Therapeutics (SGMO) Stock Forecast & Price Target
Sangamo Therapeutics (SGMO) Analyst Ratings
Bulls say
Sangamo Therapeutics has received FDA agreement to leverage data from its Phase 1/2 STAAR trial to support an Accelerated Approval BLA filing for isa-vec, a gene therapy for symptomatic Fabry disease, which underscores the potential for favorable regulatory momentum. The trial results indicate significant improvements in renal function, illustrated by a positive mean annualized estimated glomerular filtration rate (eGFR) slope, while also demonstrating durable increases in α-Gal A activity and meaningful enhancements in patient-reported outcomes over extended treatment durations. Given the advancements in its Priority Neurology Pipeline and the promising data surrounding isa-vec and its safety profile, the outlook for Sangamo Therapeutics appears robust as the company approaches critical milestones in its development programs.
Bears say
Sangamo Therapeutics Inc is facing significant challenges in its financial performance, marked by a lack of successful product commercialization and prolonged timelines for clinical trials, which have led to increased operational losses. The company's reliance on a diverse but unproven pipeline of therapies in multiple therapeutic areas raises concerns about the viability and market potential of its developmental programs amidst intensifying competition in the genomic medicine sector. Additionally, the necessity for continuous capital raises to fund ongoing research and development could further dilute shareholder value, which reinforces a cautious outlook regarding the sustainability of its business model.
This aggregate rating is based on analysts' research of Sangamo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sangamo Therapeutics (SGMO) Analyst Forecast & Price Prediction
Start investing in Sangamo Therapeutics (SGMO)
Order type
Buy in
Order amount
Est. shares
0 shares